Figure 4

DDIAS and MYBL1 are SCFD2 downstream target genes and associated with worse prognosis in ER-positive breast cancer. (A,B) DDIAS (A) and MYBL1 (B) mRNA expression in normal breast tissues (Breast), invasive ductal breast carcinoma (IDC), and invasive lobular breast carcinoma (ILC) based on TCGA breast cancer dataset retrieved from the Oncomine™ Platform (www.oncomine.org). (C,D) Relapse-free survival of ER-positive breast cancer patients with high or low mRNA expression of DDIAS (C) or MYBL1 (D) analyzed by online Kaplan–Meier plotter (http://kmplot.com/). (E–J) SCFD2 (E,H), DDIAS (F,I), and MYBL1 (G,J) mRNA levels in MCF-7 and OHTR cells transfected with control (siControl) or SCFD2-specific (siSCFD2 #1 and #2) siRNAs (10 nM) were analyzed by qRT-PCR. Relative expression levels of these mRNAs were normalized to GAPDH mRNA level in each sample and presented as mean fold ± SEM compared with siControl (n = 3). (K,L) Relative expression levels of DDIAS (K) and MYBL1 (L) mRNAs in MCF-7 and OHTR cells were normalized to GAPDH mRNA level in each sample and presented as mean fold ± SEM compared with siControl (n = 3). **P < 0.01; ***P < 0.001, two-way ANOVA performed in Fig. 5E–J. **P < 0.01; ***P < 0.001, Student’s t-test performed in Fig. 5K,L .